Abstract 1956
Background
Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC.
Methods
cross-sectional study of CRPC patients including chemo-naïve metastatic (mCRPC) or high risk M0CRPC (PSADT ≤ 10mo) in routine clinical practice. Fatigue and Quality of Life (QoL) data were collected using validated patient self-reported questionnaires(BFI-SF and FACT-G/P). Fatigue correlation with both patient's and physiciańs perception was assessed.
Results
235 patients were recruited (Jan-Sept 2015). Median age: 75.1 (46.2-92.4), median PSA: 17.8 ng/ml (0-2000), metastatic disease: 68.5%, ECOG 0-1: 90.6%. There was a high prevalence of fatigue (M1:73.9%; M0: 74.3%), with 38.3% of the patients having moderate or severe fatigue. High concordance existed between fatigue physiciańs and patient's perception (Kappa index: 0.818). Cardiovascular and respiratory disorders were associated with an increase of fatigue in the multivariate analysis (OR: 4.7 and 3.6 respectively, p
Conclusions
Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naïve CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. Table.
| FACT-G total score | FACT-P total score | |||||
|---|---|---|---|---|---|---|
| FATIGUE | Mean | SD | N | Mean | SD | N |
| Abscence | 88.0 | 13.3 | 60 | 127.7 | 16.9 | 60 |
| Mildly | 79.3 | 12.9 | 84 | 110.1 | 16.3 | 84 |
| Moderate | 71.5 | 14.7 | 64 | 110.8 | 19.3 | 64 |
| Severe | 63.2 | 19.2 | 25 | 87.7 | 25.1 | 25 |
| p-valor* | Clinical trial identificationLegal entity responsible for the studyJannsen-Cilag, Spain FundingJanssen-Cilag, Spain DisclosureAll authors have declared no conflicts of interest. Resources from the same sessionZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)Presenter: Bijal Shah Session: Poster display Resources: Abstract ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)Presenter: Michael Wang Session: Poster Display Resources: Abstract ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)Presenter: Sattva Neelapu Session: Poster Display Resources: Abstract Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-upPresenter: Maria Teresa Martinez Session: Poster display Resources: Abstract Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Presenter: Christy Toms Session: Poster display Resources: Abstract Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)Presenter: Géraldine Perkins Session: Poster display Resources: Abstract What is the optimal annual interpretive volume for a radiologist reading screening mammograms?Presenter: Asli Uluturk Session: Poster display Resources: Abstract What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian studyPresenter: Poonamalle Padmanabhan Bapsy Session: Poster display Resources: Abstract Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in PortugalPresenter: Ana Castro Session: Poster display Resources: Abstract Wait times for diagnosis and treatment of lung cancer: a single centre experiencePresenter: Catherine Labbe Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||